An Experimental Single-Time Treatment Slashed Cholesterol for a Year

A gene therapy trial has yielded surprising results: a single treatment has maintained reduced cholesterol levels for a year. The trial, conducted by CRISPR Therapeutics, involved the gene-editing therapy CTX310. The Cleveland Clinic led the first-in-human trial, which also showed continuous lowering of triglycerides. The therapy's success has drawn attention from investors, with CRSP shares reacting to the promising data.

The New York Times and KCRA have covered the medical implications, focusing on the potential for a lifelong solution to high cholesterol. The therapy's long-term effects and broader applications are still under investigation. The Cleveland Clinic's involvement lends credibility to the trial's findings. The New York Times and KCRA have covered the medical implications, focusing on the potential for a lifelong solution to high cholesterol.

The therapy's success has drawn attention from investors, with CRSP shares reacting to the promising data. Investors and medical professionals will be watching for further trials and regulatory approvals. The therapy's potential to revolutionize cholesterol management is significant. The Cleveland Clinic's role in the trial underscores the importance of ongoing research and development in gene-editing therapies.